X

Trial Profile

A real world study analysing evidence of 18F-Fluciclovine Pet/Ct utilization for recurrent Prostate Cancer

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 08 Dec 2021

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Fluciclovine 18F (Primary)
Indications Prostate cancer
Focus Diagnostic use

Most Recent Events

30 Nov 2021 According to a Blue Earth Diagnostics media release, data from this trial will be presented at the upcoming 22nd Annual Scientific Meeting in Urologic Oncology (SUO).
28 Oct 2021 New trial record
13 Sep 2021 Primary endpoint has been met. (result of 18F-fluciclovine PET/CT), as per Results presented at the 116th Annual Meeting of the American Urological Association

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com